Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, People's Republic of China.
Sci Rep. 2021 Mar 15;11(1):6048. doi: 10.1038/s41598-021-83802-z.
To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn't need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019, of 225 had prebiopsy negative bpMRI (defined as Prostate Imaging Reporting and Data System (PI-RADS 2.1) score less than 3). The detection efficiency of clinically significant prostate cancer (CSPCa) was assessed according to age, digital rectal examination (DRE), prostate volume (PV) on bpMRI, prostate-specific antigen (PSA) and PSA density (PSAD). The definition of CSPCa for Gleason score > 6. Univariate and multivariable logistic regression analysis were used to identify predictive factors of absent CSPCa on PBs. Moreover, absent CSPCa contained clinically insignificant prostate cancer (CIPCa) and benign result. The detection rates of present prostate cancer (PCa) and CSPCa were 27.11% and 16.44%, respectively. Patients who were diagnosed as CSPCa had an older age (P < 0.001), suspicious DRE (P < 0.001), a smaller PV (P < 0.001), higher PSA value (P = 0.008) and higher PSAD (P < 0.001) compared to the CIPCa group and benign result group. PSAD < 0.15 ng/ml/cm (P = 0.004) and suspicious DRE (P < 0.001) were independent predictors of absent CSPCa on BPs. The negative forecast value of bpMRI for BP detection of CSPCa increased with decreasing PSAD, mainly in patients with naive PB (P < 0.001) but not in prior negative PB patients. 25.33% of the men had the combination of negative bpMRI, PSAD < 0.15 ng/ml/cm and PB naive, and none had CSPCa on repeat PBs. The incidence of PB was determined, CSPCa was 1.59%, 0% and 16.67% in patients with negative bpMRI and PSAD < 0.15 ng/ml/cm, patients with negative bpMRI, PSAD < 0.15 ng/ml/cm and biopsy naive and patients with negative bpMRI, PSAD < 0.15 ng/ml/cm and prior negative PB, separately. We found that a part of patients with negative bpMRI, a younger age, no suspicious DRE and PSAD < 0.15 ng/ml/cm may securely avoid PBs. Conversely PB should be considered in patients regardless of negative bpMRI, especially who with a greater age, obviously suspicious DRE, significantly increased PSA value, a significantly small PV on MRI and PSAD > 0.15 ng/ml/cm.
分析 225 例前列腺影像报告和数据系统(PI-RADS)评分<3 分的前列腺磁共振成像(bpMRI)阴性而无需进行前列腺活检(PBs)的患者的临床特征。共纳入 2018 年 3 月至 2019 年 11 月在南京医科大学第一附属医院行 PBs 的 1012 例男性患者,其中 225 例患者具有术前 bpMRI 阴性(定义为 PI-RADS 2.1 评分<3)。根据年龄、直肠指检(DRE)、bpMRI 上的前列腺体积(PV)、前列腺特异性抗原(PSA)和 PSA 密度(PSAD)评估临床上显著的前列腺癌(CSPCa)的检出效率。CSPCa 的 Gleason 评分定义为>6。采用单变量和多变量逻辑回归分析确定 PB 上无 CSPCa 的预测因素。此外,无 CSPCa 包括临床意义不显著的前列腺癌(CIPCa)和良性结果。PCa 和 CSPCa 的检出率分别为 27.11%和 16.44%。与 CIPCa 组和良性结果组相比,诊断为 CSPCa 的患者年龄更大(P<0.001)、DRE 可疑(P<0.001)、PV 更小(P<0.001)、PSA 值更高(P=0.008)和 PSAD 更高(P<0.001)。PSAD<0.15ng/ml/cm(P=0.004)和可疑 DRE(P<0.001)是 BP 上无 CSPCa 的独立预测因素。随着 PSAD 的降低,bpMRI 对 CSPCa 的 BP 检测的阴性预测值增加,主要在初次 PB 阴性的患者中(P<0.001),但在先前 PB 阴性的患者中没有增加。25.33%的男性具有 bpMRI 阴性、PSAD<0.15ng/ml/cm 和 PB 初次阴性的组合,且在重复 PBs 中均无 CSPCa。PB 检出率为阴性 bpMRI 且 PSAD<0.15ng/ml/cm 组为 1.59%,阴性 bpMRI、PSAD<0.15ng/ml/cm 和初次阴性 PB 组为 0%,阴性 bpMRI、PSAD<0.15ng/ml/cm 和先前 PB 阴性组为 16.67%。我们发现,一部分具有阴性 bpMRI、年龄较小、无可疑 DRE 和 PSAD<0.15ng/ml/cm 的患者可以安全避免 PBs。相反,无论 bpMRI 是否阴性,尤其是年龄较大、DRE 明显可疑、PSA 值明显升高、MRI 上 PV 明显缩小和 PSAD>0.15ng/ml/cm 的患者,均应考虑进行 PB。